Literature DB >> 29437961

Hepatitis B Virus DNA Integration Occurs Early in the Viral Life Cycle in an In Vitro Infection Model via Sodium Taurocholate Cotransporting Polypeptide-Dependent Uptake of Enveloped Virus Particles.

Thomas Tu1, Magdalena A Budzinska2, Florian W R Vondran3,4, Nicholas A Shackel2,5,6, Stephan Urban7,8.   

Abstract

Chronic infection by hepatitis B virus (HBV) is the major contributor to liver disease worldwide. Though HBV replicates via a nuclear episomal DNA (covalently closed circular DNA [cccDNA]), integration of HBV DNA into the host cell genome is regularly observed in the liver in infected patients. While reported as a prooncogenic alteration, the mechanism(s) and timing of HBV DNA integration are not well understood, chiefly due to the lack of in vitro infection models that have detectable integration events. In this study, we have established an in vitro system in which integration can be reliably detected following HBV infection. We measured HBV DNA integration using inverse nested PCR in primary human hepatocytes, HepaRG-NTCP, HepG2-NTCP, and Huh7-NTCP cells after HBV infection. Integration was detected in all cell types at a rate of >1 per 10,000 cells, with the most consistent detection in Huh7-NTCP cells. The integration rate remained stable between 3 and 9 days postinfection. HBV DNA integration was efficiently blocked by treatment with a 200 nM concentration of the HBV entry inhibitor Myrcludex B, but not with 10 μM tenofovir, 100 U of interferon alpha, or a 1 μM concentration of the capsid assembly inhibitor GLS4. This suggests that integration of HBV DNA occurs immediately after infection of hepatocytes and is likely independent of de novo HBV genome replication in this model. Site analysis revealed that HBV DNA integrations were distributed over the entire human genome. Further, integrated HBV DNA sequences were consistent with double-stranded linear HBV DNA being the major precursor. Thus, we have established an in vitro system to interrogate the mechanisms of HBV DNA integration.IMPORTANCE Hepatitis B virus (HBV) is a common blood-borne pathogen and, following a chronic infection, can cause liver cancer and liver cirrhosis. Integration of HBV DNA into the host genome occurs in all known members of the Hepadnaviridae family, despite this form not being necessary for viral replication. HBV DNA integration has been reported to drive liver cancer formation and persistence of virus infection. However, when and the mechanism(s) by which HBV DNA integration occurs are not clear. In this study, we have developed and characterized an in vitro system to reliably detect HBV DNA integrations that result from a true HBV infection event and that closely resemble those found in patient tissues. Using this model, we showed that integration occurs when the infection is first established. Importantly, we provide here a system to analyze molecular factors involved in HBV integration, which can be used to develop strategies to halt its formation.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  HBV DNA integration; HBV double-stranded linear DNA; Myrcludex B; hepatocellular carcinoma; inverse nested PCR; microhomology-mediated end joining; nonhomologous end joining

Mesh:

Substances:

Year:  2018        PMID: 29437961      PMCID: PMC5952132          DOI: 10.1128/JVI.02007-17

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  67 in total

1.  Proliferation of primary human hepatocytes and prevention of hepatitis B virus reinfection efficiently deplete nuclear cccDNA in vivo.

Authors:  Lena Allweiss; Tassilo Volz; Katja Giersch; Janine Kah; Giuseppina Raffa; Joerg Petersen; Ansgar W Lohse; Concetta Beninati; Teresa Pollicino; Stephan Urban; Marc Lütgehetmann; Maura Dandri
Journal:  Gut       Date:  2017-04-20       Impact factor: 23.059

Review 2.  A mutator phenotype in cancer.

Authors:  L A Loeb
Journal:  Cancer Res       Date:  2001-04-15       Impact factor: 12.701

3.  Detection of Hepatocyte Clones Containing Integrated Hepatitis B Virus DNA Using Inverse Nested PCR.

Authors:  Thomas Tu; Allison R Jilbert
Journal:  Methods Mol Biol       Date:  2017

4.  A Slow Maturation Process Renders Hepatitis B Virus Infectious.

Authors:  Stefan Seitz; Caroline Iancu; Tassilo Volz; Walter Mier; Maura Dandri; Stephan Urban; Ralf Bartenschlager
Journal:  Cell Host Microbe       Date:  2016-06-16       Impact factor: 21.023

5.  Integration of hepatitis B virus DNA into chromosomal DNA during acute hepatitis B.

Authors:  Gerald C Kimbi; Anna Kramvis; Michael C Kew
Journal:  World J Gastroenterol       Date:  2005-11-07       Impact factor: 5.742

Review 6.  Efficiency of carcinogenesis: is the mutator phenotype inevitable?

Authors:  Robert A Beckman
Journal:  Semin Cancer Biol       Date:  2010-10-08       Impact factor: 15.707

7.  Antiviral activity of various interferons and pro-inflammatory cytokines in non-transformed cultured hepatocytes infected with hepatitis B virus.

Authors:  Nathalie Isorce; Barbara Testoni; Maëlle Locatelli; Judith Fresquet; Michel Rivoire; Souphalone Luangsay; Fabien Zoulim; David Durantel
Journal:  Antiviral Res       Date:  2016-03-10       Impact factor: 5.970

8.  Detection of clonally expanded hepatocytes in chimpanzees with chronic hepatitis B virus infection.

Authors:  William S Mason; Huey-Chi Low; Chunxiao Xu; Carol E Aldrich; Catherine A Scougall; Arend Grosse; Andrew Clouston; Deborah Chavez; Samuel Litwin; Suraj Peri; Allison R Jilbert; Robert E Lanford
Journal:  J Virol       Date:  2009-06-17       Impact factor: 5.103

9.  Chromosomal translocations in human cells are generated by canonical nonhomologous end-joining.

Authors:  Hind Ghezraoui; Marion Piganeau; Benjamin Renouf; Jean-Baptiste Renaud; Annahita Sallmyr; Brian Ruis; Sehyun Oh; Alan E Tomkinson; Eric A Hendrickson; Carine Giovannangeli; Maria Jasin; Erika Brunet
Journal:  Mol Cell       Date:  2014-09-04       Impact factor: 17.970

10.  The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013.

Authors:  Jeffrey D Stanaway; Abraham D Flaxman; Mohsen Naghavi; Christina Fitzmaurice; Theo Vos; Ibrahim Abubakar; Laith J Abu-Raddad; Reza Assadi; Neeraj Bhala; Benjamin Cowie; Mohammad H Forouzanfour; Justina Groeger; Khayriyyah Mohd Hanafiah; Kathryn H Jacobsen; Spencer L James; Jennifer MacLachlan; Reza Malekzadeh; Natasha K Martin; Ali A Mokdad; Ali H Mokdad; Christopher J L Murray; Dietrich Plass; Saleem Rana; David B Rein; Jan Hendrik Richardus; Juan Sanabria; Mete Saylan; Saeid Shahraz; Samuel So; Vasiliy V Vlassov; Elisabete Weiderpass; Steven T Wiersma; Mustafa Younis; Chuanhua Yu; Maysaa El Sayed Zaki; Graham S Cooke
Journal:  Lancet       Date:  2016-07-07       Impact factor: 79.321

View more
  52 in total

1.  A global scientific strategy to cure hepatitis B.

Authors:  Peter A Revill; Francis V Chisari; Joan M Block; Maura Dandri; Adam J Gehring; Haitao Guo; Jianming Hu; Anna Kramvis; Pietro Lampertico; Harry L A Janssen; Massimo Levrero; Wenhui Li; T Jake Liang; Seng-Gee Lim; Fengmin Lu; M Capucine Penicaud; John E Tavis; Robert Thimme; Fabien Zoulim
Journal:  Lancet Gastroenterol Hepatol       Date:  2019-04-10

2.  Efficient Inhibition of Hepatitis B Virus (HBV) Replication and cccDNA Formation by HBV Ribonuclease H Inhibitors during Infection.

Authors:  Ranjit Chauhan; Qilan Li; Molly E Woodson; Makafui Gasonoo; Marvin J Meyers; John E Tavis
Journal:  Antimicrob Agents Chemother       Date:  2021-09-13       Impact factor: 5.191

Review 3.  The evolution and clinical impact of hepatitis B virus genome diversity.

Authors:  Peter A Revill; Thomas Tu; Hans J Netter; Lilly K W Yuen; Stephen A Locarnini; Margaret Littlejohn
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-05-28       Impact factor: 46.802

Review 4.  Use of HBsAg quantification in the natural history and treatment of chronic hepatitis B.

Authors:  Lung-Yi Mak; Wai-Kay Seto; James Fung; Man-Fung Yuen
Journal:  Hepatol Int       Date:  2019-11-19       Impact factor: 6.047

5.  Integration of hepatitis B virus DNA into p21-activated kinase 3 (PAK3) gene in HepG2.2.15 cells.

Authors:  Peng Ruan; Xiufang Dai; Jun Sun; Chunping He; Chao Huang; Rui Zhou; Isabelle Chemin
Journal:  Virus Genes       Date:  2020-01-02       Impact factor: 2.332

Review 6.  Therapeutic Genome Editing and In Vivo Delivery.

Authors:  Amanda Catalina Ramirez-Phillips; Dexi Liu
Journal:  AAPS J       Date:  2021-06-02       Impact factor: 4.009

Review 7.  Immunobiology and pathogenesis of hepatitis B virus infection.

Authors:  Matteo Iannacone; Luca G Guidotti
Journal:  Nat Rev Immunol       Date:  2021-05-17       Impact factor: 53.106

Review 8.  Genomics of Viral Hepatitis-Associated Liver Tumors.

Authors:  Camille Péneau; Jessica Zucman-Rossi; Jean-Charles Nault
Journal:  J Clin Med       Date:  2021-04-22       Impact factor: 4.241

9.  Targeting Hepatitis B Virus Covalently Closed Circular DNA and Hepatitis B Virus X Protein: Recent Advances and New Approaches.

Authors:  Nicholas A Prescott; Yaron Bram; Robert E Schwartz; Yael David
Journal:  ACS Infect Dis       Date:  2019-09-27       Impact factor: 5.084

Review 10.  Unique Features of Hepatitis B Virus-Related Hepatocellular Carcinoma in Pathogenesis and Clinical Significance.

Authors:  Sheng-Han Wang; Shiou-Hwei Yeh; Pei-Jer Chen
Journal:  Cancers (Basel)       Date:  2021-05-18       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.